Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized Treat and Extend (TAE) regimen.
Phase of Trial: Phase IV
Latest Information Update: 24 Mar 2017
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AFLIRAP
- 24 Mar 2017 Status changed from recruiting to completed.
- 31 Jul 2014 New trial record